198 related articles for article (PubMed ID: 15212700)
1. Current approaches to first-line treatment of advanced colorectal cancer.
Goldberg RM
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S9-15. PubMed ID: 15212700
[TBL] [Abstract][Full Text] [Related]
2. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Kuebler JP; de Gramont A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794
[TBL] [Abstract][Full Text] [Related]
3. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
[TBL] [Abstract][Full Text] [Related]
4. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
Carnaghi C; Zucali P; Garassino I
Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
[TBL] [Abstract][Full Text] [Related]
5. Current status of second-line therapy for metastatic colorectal cancer.
Rothenberg ML
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S16-21. PubMed ID: 15212701
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
Zhuang L; Bai J; Huang H; Tang C; Yang J; Zhou B; Gong Y; Duanmu Z; Chen J
Oncol Res; 2010; 18(9):437-44. PubMed ID: 20524401
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer: integrating oxaliplatin.
Louvet C; de Gramont A
Curr Treat Options Oncol; 2003 Oct; 4(5):405-11. PubMed ID: 12941200
[TBL] [Abstract][Full Text] [Related]
9. Current treatments and future perspectives in colorectal and gastric cancer.
Wilke HJ; Van Cutsem E
Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Fisher MD
Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
[No Abstract] [Full Text] [Related]
11. Chemotherapy for metastatic colorectal cancer.
Rosales J; Leong LA
J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
[TBL] [Abstract][Full Text] [Related]
12. Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
Popov IP; Jelic SB; Matijasevic MM; Grbic B; Babic DR
J Exp Clin Cancer Res; 2004 Sep; 23(3):395-401. PubMed ID: 15595627
[TBL] [Abstract][Full Text] [Related]
13. [The new chemotherapy of colorectal cancers].
Taïeb J; Boige V; Ducreux M
Presse Med; 2002 Jan; 31(3):132-8. PubMed ID: 11859739
[TBL] [Abstract][Full Text] [Related]
14. Current perspectives in the treatment of metastatic colorectal cancer.
Köhne CH; Folprecht G
Ann Oncol; 2004; 15 Suppl 4():iv43-53. PubMed ID: 15477334
[No Abstract] [Full Text] [Related]
15. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Cao S; Bhattacharya A; Durrani FA; Fakih M
Expert Opin Pharmacother; 2006 Apr; 7(6):687-703. PubMed ID: 16556086
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Punt CJ
Ann Oncol; 2005 Jun; 16(6):845-6. PubMed ID: 15890668
[No Abstract] [Full Text] [Related]
19. Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
Clin Colorectal Cancer; 2003 Aug; 3(2):89-91. PubMed ID: 12952563
[No Abstract] [Full Text] [Related]
20. Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Kuramochi H; Ando M; Itabashi M; Nakajima G; Kawakami K; Hamano M; Hirai E; Yokomizo H; Okuyama R; Araida T; Yoshimatsu K; Kameoka S; Hayashi K
Cancer Chemother Pharmacol; 2017 Mar; 79(3):579-585. PubMed ID: 28213683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]